|
Variable
|
SRS and ipilimumab
|
SRS and nivolumab
| |
|---|
|
N = 45
|
N = 35
|
p
|
|---|
|
Sex (F/M)
|
17/28
|
14/21
|
1.0
|
|
Age (years)
|
|
median
|
54
|
56
|
0.2
|
|
range
|
23–78
|
26–80
| |
|
KPS
| | |
0.8
|
|
median
|
80
|
80
| |
|
60–70
|
13
|
9
| |
|
80–100
|
32
|
26
| |
|
BRAF mutation
| | |
0.8
|
|
present
|
15
|
13
| |
|
absent
|
30
|
22
| |
|
undetermined
| | | |
|
Extracranial disease
| | |
0.7
|
|
present
|
34
|
25
| |
|
absent
|
11
|
10
| |
|
Number of metastases
| |
0.4
|
|
single
|
8
|
9
| |
|
multiple
|
37
|
26
| |
|
DS-GPA
| | |
0.3
|
|
0–1
|
9
|
6
| |
|
1.5–2.5
|
22
|
16
| |
|
3–4
|
14
|
13
| |
|
Type of SRS
| | |
0.76
|
|
Single-fraction SRS
|
153
|
132
| |
|
Fractionated SRS
|
22
|
19
| |
|
Size of metastases
| | |
0.8
|
|
< 2 cm
|
99
|
84
| |
|
2–3 cm
|
46
|
38
| |
|
≥ 3 cm
|
30
|
29
| |
|
Total tumor volume (cm
3
)
| | |
0.1
|
|
median
|
7.4
|
9.2
| |
|
range
|
0.5–33.1
|
0.7–33
| |
|
GTV (cm
3
)
| | |
0.6
|
|
median
|
1.12
|
1.2
| |
|
range
|
0.05–27.9
|
0.4–31.2
| |
|
PTV (cm
3
)
| | |
0.3
|
|
median
|
1.71
|
1.83
| |
|
range
|
0.1–39.1
|
0.09–42.6
| |
|
Conformity index
a
| | |
0.5
|
|
median
|
1.43
|
1.41
| |
|
range
|
1.10–1.91
|
1.12–1.85
| |
- SRS stereotactic radiosurgery, KPS Karnofsky Performance Status
- DS-GPA Diagnosis-Specific Graded Prognostic Factors, GTV Gross Target Volume
- PTV Planning Target Volume, acalculated as prescribed isodose volume/tumor volume
- encompassed by the prescription isodose volume
